Low latency REST APIs to access more than 30 million abstracts of published articles. 

One of the primary sources for medical evidence is published articles. Published articles include supporting evidence generated from scientific research, case reports of patients, meta-analysis, clinical trials, and review articles. There are more than 30 million published articles in Medline/PubMed with available abstracts. Fast access to articles abstracts enables computers to efficiently utilize them as the primary step in systematic evidence capture. 

Nucleati Abstracts solves this problem by providing few simple REST-API endpoints to easily access millions of abstracts and provide data for evidence-based medicine discoveries. 

REST APIs  -  Abstracts
~1300 case reports of hereditary cancers collected and curated by AI

Germline variations in nearly 200 genes play a direct or indirect role in cancer predisposition. Germline Cancer Evidence Base is a one-of-its-kind AI curated evidence base that provides easy access to evidence of associations between germline genetic variation and cancer.

~5000 AI collected and curated articles with reports of adverse drug reactions

According to the Food and Drug Administration (FDA) of the United States, Adverse Drug Reactions (ADRs) are a leading cause of morbidity and mortality in hospitals. Nearly 7000 estimated ADR-related deaths occur per year in the US. With the power of Nucleati’s custom-built AI, streamlined curation workflow, and distributed team of curators, we are developing a first-of-its-kind database with evidence of ADRs. This database will provide a single platform to find, filter, and utilize valuable information about ADRs.  

REST APIs  -  Abstracts
NLP Tools for Format Interchange

We are proud to produce tools for format interchange and analysis for everyday named-entity recognition tasks.

Nucleati is dedicated to developing tools that automate actionable evidence extraction from peer-reviewed and published scientific articles. With our NLP utilities, we are proud to supply this technology to evidence-based medicine practices everywhere.